Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers
NCT ID NCT07519187
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize and attack cancer cells that carry two specific markers (CD70 and BCMA), and infusing them back. The study will enroll 20 participants to primarily evaluate safety and find the right dose, while also looking at how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR 70-BCMA dual-target CAR-T cells (a type of gene therapy that re-engineers a patient's own immune cells to attack cancer)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat plasma cell cancers like multiple myeloma.
What could go wrong
This is a very early, small trial (20 people) focused mainly on safety. The therapy may not work or could cause serious side effects, and it is not yet known if it will lead to long-term disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Western Theater Command of PLA
RECRUITINGChengdu, Chengdu, China